Aciclovir (IV) | Neonatal dosing | Amber |
Aciclovir (IV) | HSV Encephalitis infants (over 2 months old) and children | Amber |
Albendazole | Snail and Slug Ingestion - Prophylaxis against Angiostrongylus cantonensis infection (rat lung worm) | Amber |
Amikacin (IV) | Cystic fibrosis Non Tuberculous Mycobacterium infection | Red |
Amikacin (inhaled/ nebulised) | Cystic fibrosis Non Tuberculous Mycobacterium infection | Red |
Amoxicillin/ Clavulanic acid (IV) | Medication use guideline | Amber |
Amoxicillin/ Clavulanic acid (IV) | Dog bite, animal bite, retropharyngeal abscess | Amber |
Amoxicillin/ Clavulanic acid (IV) | Appendicitis COMPLICATED (e.g. perforation, appendiceal collection / abscess), Peritonitis, Necrotising enterocolitis | Amber |
Amoxicillin (oral) | Periapical Abscess | Green |
Amoxicillin (oral) | Periodontal Abscess | Green |
Amoxicillin (oral) | Pericoronitis | Green |
Amoxicillin (oral) | Alveolar Osteitis | Green |
Amoxicillin (oral) | Avulson (up to 8 years of age) | Green |
Oral amoxicillin challenge (Low risk) | CHQ-GDL-01076 Paediatric antibiotic allergy assessment, testing and de-labelling | Amber |
Amoxycillin (Amoxicillin) (IV) | Neonatal dosing | Green |
Amoxycillin (Amoxicillin) (IV) | Appendicitis (UNCOMPLICATED, no perforation) | Green |
Amoxycillin (Amoxicillin) (PO) | Acute otitis media | Green |
Amoxycillin (Amoxicillin) (PO) | Community acquired pneumonia (CAP) oral antibiotics Infants and children (more than 1 month old) (non PICU) | Green |
Amoxycillin (Amoxicillin) (PO) | Non-typhoidal Salmonellosis in Children | Green |
Amoxycillin / Clavulanic acid (Amoxicillin / Clavulanic acid) (PO) | Cystic fibrosis Outpatient | Green |
Amoxycillin / Clavulanic acid (Amoxicillin / Clavulanic acid) (PO) | Non CF bronchiectasis Outpatient | Green |
Amoxycillin / Clavulanic acid (Amoxicillin / Clavulanic acid) (PO) | Appendicitis (Early IV to oral switch) | Green |
Amoxycillin / Clavulanic acid (Amoxicillin / Clavulanic acid) (PO) | Animal bites or wounds inflicted by animal (non PICU) (Early IV to oral switch) | Green |
Amoxicillin/clavulanate (IV) | Facial Cellulitis (of Dental Origin) | Amber |
Amoxicillin/clavulanate (oral) | Facial Cellulitis (of Dental Origin) | Green |
Amphotericin B Liposomal (Ambisome) (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Amber |
Ampicillin (IV) | Neonatal dosing | Green |
Ampicillin (IV) | Urinary tract infection/ Pyelonephritis (infants and children) | Green |
Ampicillin (IV) | Appendicitis (UNCOMPLICATED, no perforation) | Green |
Anidulafungin (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Artemether/ Lumefantrine (Riamet) (PO) | Plasmodium falciparum Malaria | Red |
Artesunate (SAS) (IV) | Severe/complicated Plasmodium falciparum Malaria | Red |
Atovaquone/ Proguanil (Malarone ) (PO) | Plasmodium falciparum Malaria | Red |
Azithromycin (IV) | Severe pneumonia (PICU) | Amber |
Azithromycin (IV) | Pertussis (PICU) | Amber |
Azithromycin (Oral) | Non CF bronchiectasis – anti-inflammatory for CSLD | Amber |
Azithromycin (PO) | Pertussis (non PICU) | Amber |
Azithromycin (PO) | Cystic fibrosis anti-inflammatory (chronic lung disease) | Amber |
Azithromycin (PO) | Non-typhoidal Salmonellosis in Children | Amber |
Azithromycin (PO) | Cystic fibrosis non tuberculous mycobacterium infection (NTM) | Amber |
Aztreonam lysine (SAS) (inhaled/nebulised) | Cystic fibrosis Outpatient | Red |
Aztreonam (IV) | Cystic fibrosis pulmonary optimization | Red |
Aztreonam (IV) | Liver transplant prophylaxis for patients with penicillin/cephalosporin anaphylaxis | Red |
Aztreonam (IV) | Renal transplant prophylaxis for patients with penicillin/cephalosporin anaphylaxis | Red |
Benzylpenicillin (IV) | Neonatal dosing | Green |
Benzylpenicillin (IV) | Amputations prophylaxis | Green |
Benzylpenicillin (IV) | Endocarditis | Green |
Benzylpenicillin (IV) | Community acquired pneumonia (CAP) intravenous antibiotics Infants and children (more than 1 month old) or Empyema (non PICU) | Green |
Casirivimab-Imdevimab | CHQ-GDL-63327 – The Management of Children with COVID-19 (QCH) (health.qld.gov.au) | Red |
Caspofungin (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Cefalexin (PO) | Cystic fibrosis Outpatient | Green |
Cefalexin (PO) | Mild cellulitis, peri-orbital cellulitis, impetigo, cervical lymphadenitis | Green |
Cefazolin 5 % eye drops | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Amber |
Cefazolin (IV) | Cystic fibrosis Pulmonary optimization | Green |
Cefazolin (IV) | General Surgical antibiotic prophylaxis (refer to guideline for specific surgery recommendations) | Green |
Cefazolin (IV) | Bone and joint infections (Osteomyelitis and septic arthritis) | Green |
Cefazolin (IV) | Compound fractures - Open fractures NO severe tissue damage/ NO evidence of infection | Green |
Cefazolin (IV) | Cardiac Surgical antibiotic prophylaxis | Green |
Cefazolin (IV) (ED HITH) | Hospital-In-The-Home (HITH) Emergency/ ED pathways for Cellulitis, Community acquired pneumonia, Lymphadenitis, Peri-orbital cellulitis | Amber |
Cefepime (IV) | Cystic fibrosis Pulmonary optimization | Amber |
Cefotaxime (IV) | Neonatal dosing | Amber |
Cefotaxime (IV) | Community acquired Sepsis (infants and children) | Amber |
Cefotaxime (IV) | Meningitis (infants and children) | Amber |
Cefotaxime (IV) | CSF shunt infection (infants and children) | Amber |
Cefotaxime (IV) | Severe/ life threatening pneumonia (PICU) (infants and children) | Amber |
Cefotaxime (IV) | Non CF bronchiectasis Pulmonary optimization | Amber |
Cefotaxime (IV) | Non CF bronchiectasis Pulmonary optimization | Amber |
Cefotaxime (IV) | Salmonella bacteraemia, meningitis or osteomyelitis | Amber |
Cefotaxime (IV) | Tracheitis and epiglottitis | Amber |
Cefotaxime (IV) | Mastoiditis | Amber |
Cefotaxime (IV) | Cholangitis | Amber |
Cefotaxime (IV) | Infants and children less than 5 years old and not HIB immune with Osteomyelitis, Septic arthritis, moderate to severe peri-orbital cellulitis, severe cellulitis | Amber |
Cefotaxime (IV) | Suspected necrotising fasciitis (non PICU) | Amber |
Cefoxitin (IV) | Abdominal, Kasai, Biliary surgery antibiotic prophylaxis | Amber |
Cefoxitin (IV) | Cystic fibrosis Pulmonary optimization | Amber |
Ceftazidime (IV) | Non CF bronchiectasis Pulmonary optimization | Amber |
Ceftazidime (IV) | Cystic fibrosis Pulmonary optimization | Amber |
Ceftazidime (IV) | Febrile neutropenia patients with delayed type penicillin hypersensitivity | Amber |
Ceftazidime intravitreal injection (Ophthalmologist administration) | Acute management of Open Globe Injuries (penetrating eye injury) | Amber |
Ceftriaxone (IV) | Community acquired Sepsis (infants and children) | Amber |
Ceftriaxone (IV) | Meningitis (infants and children) | Amber |
Ceftriaxone (IV) | Non CF bronchiectasis Pulmonary optimization | Amber |
Ceftriaxone (IM) | Ceftriaxone Intramuscular Dosing information (infants and children) refer to AMH Children's Dosing companion
Ceftriaxone Intramuscular dose preparation and administration refer to RCH Paediatric injectable guidelines
Guidelines for Maximal Amounts of solutions to be Injected into Muscle Tissue | Amber |
Ceftriaxone (IV) | Febrile non neutropenia | Amber |
Ceftriaxone (IV) | Salmonella bacteraemia, meningitis or osteomyelitis | Amber |
Ceftriaxone IV (ED HITH) | Hospital-In-The-Home (HITH) Emergency/ ED pathways for Cellulitis, Community acquired pneumonia, Lymphadenitis, Peri-orbital cellulitis | Amber |
Cefuroxime (PO) | Non CF bronchiectasis Outpatient | Amber |
Cefazolin intracameral injection (Ophthalmologist administration) | Acute management of Open Globe Injuries (penetrating eye injury) | Amber |
Cefazolin intravitreal injection (Ophthalmologist administration) | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Amber |
Ciprofloxacin (IV) | Cystic fibrosis Pulmonary optimization | Red |
Ciprofloxacin (IV) | Water immersed wound infection (refer to guideline for specific indications) | Red |
Ciprofloxacin (PO) | Cystic fibrosis Outpatient | Amber |
Ciprofloxacin (PO) | Non CF bronchiectasis Outpatient | Amber |
Ciprofloxacin (PO) | Neisseria meningitidis prophylaxis | Amber |
Ciprofloxacin ear drops | Otitis externa | Amber |
Ciprofloxacin/ hydrocortisone ear drops | Suspected pseudomonas otitis externa with either significant canal wall oedema or associated with myringitis | Red |
Clarithromycin (PO) | Cystic fibrosis Non tuberculous mycobacterium (NTM) | Red |
Clindamycin (IV) | Neonatal dosing | Red |
Clindamycin (PO) | Cystic fibrosis Outpatient | Amber |
Clindamycin (PO) | Plasmodium falciparum Malaria | Red |
Clindamycin (PO) | Mild cellulitis, peri-orbital cellulitis, impetigo, cervical lymphadenitis with nmMRSA risk factors or history of boils | Amber |
Clofazimine (PO) (SAS) | Cystic fibrosis Non tuberculous mycobacterium (NTM) | Red |
Colistin (IV) | Cystic fibrosis Pulmonary optimization | Red |
Colistin (nebulised) | Cystic fibrosis Outpatient | Amber |
Doxycycline (oral) | Avulsion (greater than 8 years of age) | Amber |
Doxycycline (PO) | Cystic fibrosis Outpatient | Amber |
Doxycycline (PO) | Water immersed wound infection (refer to guideline for specific indications) | Amber |
Doxycycline (PO) | Plasmodium falciparum Malaria | Red |
Ethambutol (PO) | Cystic fibrosis Non tuberculous mycobacterium (NTM) | Red |
Ethambutol (PO) | Tuberculosis | Red |
Flucloxacillin (PO) | Cystic fibrosis Outpatient | Green |
Flucloxacillin (PO) | Mild cellulitis, peri-orbital cellulitis, impetigo, cervical lymphadenitis | Green |
Flucloxacillin (IV) | Neonatal dosing | Green |
Flucloxacillin (IV) | Burns surgical debridement prophylaxis | Green |
Flucloxacillin (IV) | Water immersed wound infection (refer to guideline for specific indications) | Green |
Flucloxacillin (IV) | Endocarditis (prosthetic valve, nosocomial infection or community acquired MRSA suspected) | Green |
Flucloxacillin (IV) | Osteomyelitis, Septic arthritis, moderate to severe peri-orbital cellulitis, severe cellulitis | Green |
Fluconazole (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Fluconazole (PO) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Amber |
Flucytosine (SAS) (PO) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Fusidic acid (sodium fusidate) (PO) | Cystic fibrosis MRSA - Outpatient | Red |
Ganciclovir (IV) | Congenital CMV treatment | Red |
Gentamicin antibiotic lock (CVAD) | Antibiotic Lock Therapy for Catheter Related Blood Stream Infections | Amber |
Gentamicin (IV) | Neonatal dosing | Amber |
Gentamicin (IV) | Gentamicin dosing and therapeutic drug monitoring guideline | Amber |
Gentamicin IV (ED HITH) | Hospital-In-The-Home (HITH) Emergency/ ED pathways- Urinary tract infection/ Pyelonephritis | Amber |
Gentamicin (IV) | General Surgical antibiotic prophylaxis in patients with penicillin or cephalosporin hypersensitivity (refer to guideline for specific surgery recommendations) | Amber |
Gentamicin eye drops | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Amber |
HITH (Hospital in the home IV antimicrobials) | https://qheps.health.qld.gov.au/__data/assets/pdf_file/0016/710062/hith-guide.pdf | Red |
Imipenem/cilastatin (IV) | Cystic fibrosis Non tuberculous mycobacterium (NTM) | Red |
Isoniazid (PO) | Tuberculosis | Red |
Itraconazole (PO) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Amber |
Itraconazole (PO) | Cystic fibrosis Allergic bronchopulmonary aspergillosis (ABPA) | Amber |
Lamivudine (PO) | Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection | Red |
Lincomycin (IV) | Community acquired pneumonia with empyema (Non PICU) | Amber |
Lincomycin (IV) | General Surgical antibiotic prophylaxis in patients with penicillin or cephalosporin hypersensitivity (refer to guideline for specific surgery recommendations) | Amber |
Lincomycin (IV) | Water immersed wound infection (refer to guideline for specific indications) | Amber |
Lincomycin (IV) | Cystic fibrosis Pulmonary optimization | Amber |
Lincomycin (IV) | Severe/ life threatening pneumonia (PICU) (infants and children) | Amber |
Lincomycin (IV) | Patients at risk of nmMRSA or history of boils with Osteomyelitis, Septic arthritis, moderate to severe peri-orbital cellulitis, severe cellulitis | Amber |
Lincomycin (IV) | Suspected necrotising fasciitis (non PICU) | Amber |
Linezolid (PO and IV) | Cystic fibrosis Non Tuberculous Mycobacterium infection (NTM) | Red |
Lopinavir/ ritonavir (Kaletra) (PO) | Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection | Red |
Mebendazole (PO) | Pinworms | Amber |
Meropenem (IV) | Febrile neutropenia patients with anaphylaxis to beta lactams | Red |
Meropenem (IV) | Liver transplant prophylaxis for patients with penicillin/cephalosporin hypersensitivity | Red |
Meropenem (IV) | Renal transplant prophylaxis for patients with penicillin/cephalosporin hypersensitivity | Red |
Meropenem (IV) | Cystic fibrosis Pulmonary optimization | Red |
Meropenem (IV) | External wound or inoculation with Suspected necrotising fasciitis (non PICU) | Red |
Metronidazole (IV) | General Surgical antibiotic prophylaxis in patients with penicillin or cephalosporin hypersensitivity (refer to guideline for specific surgery recommendations) | Green |
Metronidazole (IV) | Neonatal dosing | Green |
Metronidazole (IV) | Appendicitis (UNCOMPLICATED, no perforation) | Green |
Metronidazole (IV) | Cholangitis | Amber |
Metronidazole (PO) | Clostridium difficile infection (mild/moderate) | Green |
Metronidazole (PO) | Giardiasis | Green |
Metronidazole (IV) | Severe Clostridium difficile infection | Green |
Micafungin (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Minocycline (PO) | Cystic fibrosis Outpatient | Amber |
Moxifloxacin (PO and IV) | Cystic fibrosis Outpatient | Red |
Mupirocin (intranasal ointment) | Eradication of S. aureus nasal colonisation in cardiac surgery patients | Amber |
Natamycin eye drops (SAS) | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Red |
Nevirapine (PO) | Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection | Red |
Ofloxacin eye drops | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Amber |
Oseltamivir (PO) | CDC Recommended Dosage and Duration of Treatment or Chemoprophylaxis for Influenza Antiviral Medications | Amber |
Palivizumab (IM) | RSV prophylaxis for high risk patient groups | Red |
Phenoxymethylpenicillin (PO) | Tonsillitis (non PICU) | Green |
Piperacillin/ Tazobactam (IV) | Liver transplant prophylaxis | Amber |
Piperacillin/ Tazobactam (IV) | Renal transplant prophylaxis | Amber |
Piperacillin/ Tazobactam (IV) | Febrile neutropenia | Amber |
Piperacillin/ Tazobactam (IV) | Cystic fibrosis pulmonary optimization | Amber |
Piperacillin/ Tazobactam (IV) | Non CF bronchiectasis Pulmonary optimization | Amber |
Piperacillin/ Tazobactam (IV) | Appendicitis COMPLICATED (e.g. perforation, appendiceal collection / abscess), Peritonitis, Necrotising enterocolitis | Amber |
Piperacillin/ Tazobactam (IV) | Compound fractures - Open fractures severe tissue damage/ evidence of infection | Amber |
Posaconazole (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Posaconazole (PO) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Amber |
Primaquine (PO) | Malaria Plasmodium ovale and Plasmodium vivax (note: different dosing recommendations check carefully) | Red |
Pyrazinamide (PO) (SAS) | Tuberculosis | Red |
Quinine sulfate (SAS) (PO) | Plasmodium falciparum Malaria | Red |
Remdesivir | CHQ-GDL-63327 – The Management of Children with COVID-19 (QCH) (health.qld.gov.au) | Red |
Rifampicin (PO) | Cystic fibrosis MRSA - Outpatient | Amber |
Rifampicin (PO) | Neisseria meningitidis prophylaxis | Amber |
Rifampicin (PO) | Tuberculosis | Red |
Sarilumab | CHQ-GDL-63327 – The Management of Children with COVID-19 (QCH) (health.qld.gov.au) | Red |
Sotrovimab | CHQ-GDL-63327 – The Management of Children with COVID-19 (QCH) (health.qld.gov.au) | Red |
Taurolidine/citrate antiseptic lock (Taurolock) | Use of Taurolidine/Citrate Lock Solution in the Prevention of Central Venous Catheter Related Bacteraemia | Red |
Teicoplanin (IV) | Cystic fibrosis MRSA Pulmonary optimization | Amber |
Teicoplanin (IV) | CHQ-PROC-03455 Management of Compromised Central Venous Access Device (CVAD) | Amber |
Terbinafine (PO) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Amber |
Tetanus containing vaccine | Tetanus prone wound | Green |
Tigecycline (IV) | Cystic fibrosis Non Tuberculous Mycobacterium infection (NTM) | Red |
Tobramycin (inhaled TOBI podhaler) | Cystic fibrosis - Outpatient | Amber |
Tobramycin (IV) | Neonatal dosing | Amber |
Tobramycin (IV) | Cystic fibrosis pulmonary optimization | Amber |
Tobramycin (TOBI nebulised) | Cystic fibrosis - Outpatient | Amber |
Tobramycin (TOBI nebulised) | Non CF Bronchiectasis - Outpatient | Amber |
Trimethoprim / Sulfamethoxazole (PO) | Water immersed wound infection (refer to guideline for specific indications) | Green |
Trimethoprim/ Sulfamethoxazole (IV) | Cystic fibrosis MRSA Pulmonary optimization | Amber |
Trimethoprim/ Sulfamethoxazole (PO) | Cystic fibrosis MRSA/ severe infection Outpatient | Amber |
Trimethoprim/ Sulfamethoxazole (PO) | Non-typhoidal Salmonellosis in Children | Amber |
Trimethoprim/ Sulfamethoxazole (PO) | Mild cellulitis, peri-orbital cellulitis, impetigo, cervical lymphadenitis with nmMRSA risk factors or history of boils | Green |
ValGANciclovir (PO) | Renal transplant CMV prophylaxis | Amber |
ValGANciclovir (PO) | Congenital CMV treatment | Amber |
Vancomycin antibiotic lock (CVAD) | Antibiotic Lock Therapy for Catheter Related Blood Stream Infections | Amber |
Vancomycin (IV) | Vancomycin dosing and Therapeutic drug monitoring guideline (check indication for dosing and monitoring guidance) | Amber |
Vancomycin (IV) | Neonatal dosing | Amber |
Vancomycin (SAS) (PO) | Clostridium difficile infection (moderate/severe) | Red |
Vancomycin intravitreal injection (Ophthalmologist administration) | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Amber |
Vancomycin intracameral injection (Ophthalmologist administration) | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Amber |
Voriconazole eyedrops | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Red |
Voriconazole (IV) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Red |
Voriconazole (PO) | CHQ-GDL-01075 Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and other Immunocompromised Children | Amber |
Voriconazole Intravitreal injection (Ophthalmologist administration) | Acute management of Open Globe Injuries (penetrating eye injury/ ophthalmic/ eye infections/ keratitis) | Red |
Zidovudine (SAS) (IV) | Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection | Red |
Zidovudine (PO) | Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection | Red |